Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals announced positive results from the Phase 1 trial of RP-A501 for Danon Disease. The investigational gene therapy showed sustained clinical benefits across key endpoints in four patients. Notably, three patients improved in NYHA class from II to I, indicating enhanced heart function, and significant reductions in BNP levels were recorded. The therapy was well tolerated at low doses, despite some adverse effects in high-dose patients. Rocket plans to transition to Phase 2 trials focusing on the low-dose cohort.
Rocket Pharmaceuticals (NASDAQ: RCKT) will present updated data from its ongoing Phase 1 clinical trial of RP-A501 for Danon Disease during the American Heart Association Scientific Sessions 2021, held virtually from November 13-15. A conference call will occur on November 15 at 8:30 a.m. ET to discuss the findings. Rocket's gene therapies target rare genetic disorders, including Fanconi Anemia and Leukocyte Adhesion Deficiency-I. The company emphasizes its integrated approach to developing innovative treatments for pediatric conditions.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that CEO Gaurav Shah will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 p.m. ET. A live audio webcast will be available on the company's investor website, with a replay following the conference. Rocket is focused on developing genetic therapies for rare childhood disorders, targeting conditions like Fanconi Anemia and Danon Disease. The company emphasizes its integrated pipeline and platform-agnostic approach to addressing complex medical needs in pediatric patients.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced updated clinical data from its ongoing Phase 1 trial of RP-A501 for Danon Disease, set to be presented at the AHA Scientific Sessions from November 13-15, 2021. The trial aims to evaluate the gene therapy's safety and efficacy, with preliminary results indicating it is generally well tolerated and shows improved cardiac function. Danon Disease, a rare genetic disorder, currently lacks specific treatment options, further emphasizing the potential significance of RP-A501 for patients.
Rocket Pharmaceuticals (NASDAQ: RCKT) announces upcoming presentations at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. The presentations will feature updated clinical data from three gene therapy programs targeting Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I), and Fanconi Anemia (FA). Highlights include an oral presentation on the Phase 1 study of RP-L301 for PKD and two poster presentations on RP-L201 for LAD-I and RP-L102 for FA, showcasing interim results and addressing severe unmet medical needs.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 2021 financial results with a net loss of $50.1 million or $0.79 per share, up from $29.1 million or $0.53 per share in Q3 2020. The company holds $421.5 million in cash, expected to fund operations into 2H 2023. Treatment in the Danon Disease trial commenced for pediatric patients, while the LAD-I trial reported positive interim results with favorable safety and efficacy in all seven patients. Comprehensive clinical updates are anticipated at upcoming AHA and ASH meetings.
Frazier Healthcare Partners announced the closing of Frazier Life Sciences Public Fund, raising nearly $830 million in an oversubscribed fund. This marks Frazier's first dedicated public life sciences fund, increasing total capital raised to over $7.1 billion. The fund targets investments in small- and mid-cap public biotech firms. Recent successful exits include Rocket Pharmaceuticals (NASDAQ: RCKT), Translate Bio (NASDAQ: TBIO), and Trillium Therapeutics (pending acquisition by Pfizer).
Summary not available.
Summary not available.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announces CEO Gaurav Shah will present at the 2021 Cell & Gene Meeting on the Mesa in Carlsbad, CA, on Tuesday, October 12, at 2:15 p.m. PST. The presentation will be available via a live audio webcast for registered attendees, with a recorded version accessible within 24 hours. Rocket focuses on genetic therapies for rare childhood disorders, with programs targeting conditions such as Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis, utilizing both lentiviral vector and adeno-associated virus technologies.